US20010006655A1 - Process for preparing solid formulations of lipidregulating agents with enhanced dissolution and absorption - Google Patents

Process for preparing solid formulations of lipidregulating agents with enhanced dissolution and absorption Download PDF

Info

Publication number
US20010006655A1
US20010006655A1 US09/240,515 US24051599A US2001006655A1 US 20010006655 A1 US20010006655 A1 US 20010006655A1 US 24051599 A US24051599 A US 24051599A US 2001006655 A1 US2001006655 A1 US 2001006655A1
Authority
US
United States
Prior art keywords
mixture
lipid
fenofibrate
dosage form
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/240,515
Other versions
US6368622B2 (en
Inventor
Yisheng Chen
Kevin R. Engh
Yihoung Qiu
Thomas L. Reiland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to US09/240,515 priority Critical patent/US6368622B2/en
Assigned to ABBOTT LABORATORIES reassignment ABBOTT LABORATORIES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: REILAND, THOMAS L., CHEN, YISHENG, ENGH, KEVIN R., YIHONG, QIU
Publication of US20010006655A1 publication Critical patent/US20010006655A1/en
Application granted granted Critical
Publication of US6368622B2 publication Critical patent/US6368622B2/en
Assigned to ABBVIE INC. reassignment ABBVIE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ABBOTT LABORATORIES
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Definitions

  • the present invention relates to a new process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption characteristics.
  • 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethylester, also known as fenofibrate, is representative of a broad class of compounds having pharmaceutical utility as lipid-regulating agents. More specifically, this compound is part of a lipid-regulating agent class of compounds commonly known as fibrates, and is disclosed in U.S. Pat. No. 4,058,552.
  • Fenofibrate has been prepared in several different formulations, c.f., U.S. Pat. No. 4,800,079 and U.S. Pat. No. 4,895,726.
  • U.S. Pat. No. 4,895,726 discloses a co-micronized formulation of fenofibrate and a solid surfactant.
  • U.S. Pat. No. 4,961,890 discloses a process for preparing a controlled release formulation containing fenofibrate in an intermediate layer in the form of crystalline microparticles included within pores of an inert matrix.
  • the formulation is prepared by a process involving the sequential steps of dampening said inert core with a solution based on said binder, then projecting said fenofibrate microparticles in a single layer onto said dampened core, and thereafter drying, before said solution based on said binder dissolves said fenofibrate microparticles, and repeating said three steps in sequence until said intermediate layer is formed.
  • European Patent Application No. EP0793958A2 discloses a process for producing a fenofibrate solid dosage form utilizing fenofibrate, a surface active agent and polyvinyl pyrrolidone in which the fenofibrate particles are mixed with a polyvinyl pyrrolidone solution. The thus obtained mixture is granulated with an aqueous solution of one or more surface active agents, and the granules thus produced are dried.
  • PCT Publication No. WO82/01649 discloses a fenofibrate formulation having granules that are comprised of a neutral core that is a mixture of saccharose and starch.
  • the neutral core is covered with a first layer of fenofibrate, admixed with an excipient and with a second microporous outer layer of an edible polymer.
  • U.S. Pat. No. 5,645,856 discloses the use of a carrier for hydrophobic drugs, including fenofibrate, and pharmaceutical compositions based thereon.
  • the carrier comprises a digestible oil and a pharmaceutically-acceptable surfactant component for dispersing the oil in vivo upon administration of the carrier, which comprises a hydrophilic surfactant, said surfactant component being such as not to substantially inhibit the in vivo lipolysis of the digestible oil.
  • the present invention is directed to a process for preparing a solid formulation of a lipid-regulating agent with enhanced dissolution and absorption characteristics.
  • This process comprises forming a mixture of the lipid-regulating agent with a solid surfactant, and granulating the mixture by melting, mixing, and congealing, then optionally forming a finished dosage form.
  • the mixture may be granulated by techniques well-known in the art, preferably by using a high shear granulator, a spinning disk or by spray congealing techniques.
  • the granules may be milled, if necessary, and optionally blended with conventional pharmaceutical excipients.
  • the finished oral dosage form may be prepared by techniques well-known to those skilled in the art by sizing the mixture, dry blending the resultant particles with excipients and forming the finished oral dosage form, preferably as a tablet or capsule.
  • the formulation thus produced may be administered directly as a granulated product, diluted into an appropriate vehicle for administration, encapsulated into soft or hard gelatin shells or capsules for administration, or administered by other means obvious to those skilled in the art.
  • FIG. 1 is a graph showing the dissolution characteristics of a representative composition prepared by the process of the present invention and a prior art composition.
  • FIG. 2 is a graph showing the dissolution characteristics of another representative composition prepared by the process of the present invention and a prior art composition.
  • the bulk lipid-regulating agent can be prepared by any available method, as for example the compound fenofibrate may be prepared by the procedure disclosed in U.S. Pat. No. 4,658,552, or the procedure disclosed in U.S. Pat. No. 4,739,101, both herein incorporated by reference.
  • the lipid-regulating agent is mixed with a surfactant such as, for example, poloxamer polyols (Pluronic F68, B. F. Goodrich Specialty Chemicals).
  • a surfactant such as, for example, poloxamer polyols (Pluronic F68, B. F. Goodrich Specialty Chemicals).
  • suitable surfactants include pharmaceutically-acceptable surfactants such as d-alpha tocophenyl polyethylene glycol succinate and polyoxyl 40 stearate.
  • the lipid-regulating agent/surfactant mixture is granulated by melting, mixing and congealing the mixture.
  • Other excipients such as starch, lactose, polyvinyl pyrrolidone and magnesium stearate may be added to the mixture.
  • the mixture is then granulated, prefereably by use of a high shear granulator, a spinning disk or by spray drying techniques.
  • the resulting material may be milled if necessary, and if desired, formed into a tablet or capsule by conventional techniques such as direct compression or other means.
  • each mixture was congealed at room temperature with stirring.
  • the congealed solids were milled through a 30 mesh screen using a Quadro Comill.
  • the resultant powder/granules were collected and #2 capsules were filled with 167.5 mg of granules from Example 1A (67 mg fenofibrate) and 134 mg of granules from Example 1B (67 mg of fenofibrate).
  • Fenofibrate and Pluronic F68 were melted and mixed in a 1:2 weight ration in a container at approximately 100° C. followed by congealing while mixing at room temperature. The particle size of the congealed solid was reduced to below 30 mesh by grinding and sieving. Granules containing 67 mg of fenofibrate were filled into #2 hard gelatin capsules.
  • FIGS. 1 and 2 In vitro dissolution profiles of the reference capsule and capsules from Example 1 of the current invention are shown in FIGS. 1 and 2. This data indicates that dissolution rate of the current invention is more rapid and complete than the reference. Based on U.S. Pat. No. 4,895,726, in vitro dissolution results can be correlated to the in vivo bioavailability in humans. Thus, more rapid and complete dissolution in vitro can result in higher bioavailability in humans.
  • Fenofibrate, Pluronic F68 and mannitol (4:4:2 weight ratio) were melted and mixed in a container at approximately 100° C. followed by congealing while mixing at room temperature. Particles of the congealed solid were milled through a 30 mesh screen using Quadro Comill. Granules equivalent to 67 mg fenofibrate were filled into a #2 hard gelatin capsule.

Abstract

A process for preparing a solid formulation of a lipid-regulating agent comprising forming a mixture of said lipid-regulating agent with a surfactant; granulating said mixture by melting, mixing, and congealing said mixture; and optionally forming a finished dosage form.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a new process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption characteristics. [0001]
    • BACKGROUND OF THE INVENTION
  • 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethylester, also known as fenofibrate, is representative of a broad class of compounds having pharmaceutical utility as lipid-regulating agents. More specifically, this compound is part of a lipid-regulating agent class of compounds commonly known as fibrates, and is disclosed in U.S. Pat. No. 4,058,552. [0002]
  • Fenofibrate has been prepared in several different formulations, c.f., U.S. Pat. No. 4,800,079 and U.S. Pat. No. 4,895,726. U.S. Pat. No. 4,895,726 discloses a co-micronized formulation of fenofibrate and a solid surfactant. [0003]
  • U.S. Pat. No. 4,961,890 discloses a process for preparing a controlled release formulation containing fenofibrate in an intermediate layer in the form of crystalline microparticles included within pores of an inert matrix. The formulation is prepared by a process involving the sequential steps of dampening said inert core with a solution based on said binder, then projecting said fenofibrate microparticles in a single layer onto said dampened core, and thereafter drying, before said solution based on said binder dissolves said fenofibrate microparticles, and repeating said three steps in sequence until said intermediate layer is formed. [0004]
  • European Patent Application No. EP0793958A2 discloses a process for producing a fenofibrate solid dosage form utilizing fenofibrate, a surface active agent and polyvinyl pyrrolidone in which the fenofibrate particles are mixed with a polyvinyl pyrrolidone solution. The thus obtained mixture is granulated with an aqueous solution of one or more surface active agents, and the granules thus produced are dried. [0005]
  • PCT Publication No. WO82/01649 discloses a fenofibrate formulation having granules that are comprised of a neutral core that is a mixture of saccharose and starch. The neutral core is covered with a first layer of fenofibrate, admixed with an excipient and with a second microporous outer layer of an edible polymer. [0006]
  • U.S. Pat. No. 5,645,856 discloses the use of a carrier for hydrophobic drugs, including fenofibrate, and pharmaceutical compositions based thereon. The carrier comprises a digestible oil and a pharmaceutically-acceptable surfactant component for dispersing the oil in vivo upon administration of the carrier, which comprises a hydrophilic surfactant, said surfactant component being such as not to substantially inhibit the in vivo lipolysis of the digestible oil. [0007]
  • The prior art processes obtained small particles of fenofibrate by the use of co-micronization of the drug with a surfactant. These resulting formulations may not have the maximized dissolution rate. [0008]
  • It is an object of the present invention to provide small particles of lipid-regulating agents, more preferably fenofibrate, having enhanced dissolution and absorption characteristics than those particles of such agents prepared by the prior art techniques. [0009]
    • SUMMARY OF THE INVENTION
  • The present invention is directed to a process for preparing a solid formulation of a lipid-regulating agent with enhanced dissolution and absorption characteristics. [0010]
  • This process comprises forming a mixture of the lipid-regulating agent with a solid surfactant, and granulating the mixture by melting, mixing, and congealing, then optionally forming a finished dosage form. [0011]
  • The mixture may be granulated by techniques well-known in the art, preferably by using a high shear granulator, a spinning disk or by spray congealing techniques. [0012]
  • The granules may be milled, if necessary, and optionally blended with conventional pharmaceutical excipients. [0013]
  • The finished oral dosage form may be prepared by techniques well-known to those skilled in the art by sizing the mixture, dry blending the resultant particles with excipients and forming the finished oral dosage form, preferably as a tablet or capsule. [0014]
  • The formulation thus produced may be administered directly as a granulated product, diluted into an appropriate vehicle for administration, encapsulated into soft or hard gelatin shells or capsules for administration, or administered by other means obvious to those skilled in the art. [0015]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a graph showing the dissolution characteristics of a representative composition prepared by the process of the present invention and a prior art composition. [0016]
  • FIG. 2 is a graph showing the dissolution characteristics of another representative composition prepared by the process of the present invention and a prior art composition. [0017]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The bulk lipid-regulating agent can be prepared by any available method, as for example the compound fenofibrate may be prepared by the procedure disclosed in U.S. Pat. No. 4,658,552, or the procedure disclosed in U.S. Pat. No. 4,739,101, both herein incorporated by reference. [0018]
  • The lipid-regulating agent is mixed with a surfactant such as, for example, poloxamer polyols (Pluronic F68, B. F. Goodrich Specialty Chemicals). Other suitable surfactants include pharmaceutically-acceptable surfactants such as d-alpha tocophenyl polyethylene glycol succinate and [0019] polyoxyl 40 stearate.
  • The lipid-regulating agent/surfactant mixture is granulated by melting, mixing and congealing the mixture. Other excipients, such as starch, lactose, polyvinyl pyrrolidone and magnesium stearate may be added to the mixture. The mixture is then granulated, prefereably by use of a high shear granulator, a spinning disk or by spray drying techniques. The resulting material may be milled if necessary, and if desired, formed into a tablet or capsule by conventional techniques such as direct compression or other means. [0020]
  • The invention will be understood more clearly from the following non-limiting representative examples: [0021]
    • EXAMPLE 1
  • A. 4 grams of fenofibrate and 4 grams of Pluronic F68 (B. F. Goodrich Specialty Chemicals) were melted at 100° C. 2 grams of mannitol was added with mixing. [0022]
  • B. A second sample of 6 grams of fenofibrate was melted at 100° C. 12 grams of Pluronic F68 was added with mixing. [0023]
  • Each mixture was congealed at room temperature with stirring. The congealed solids were milled through a 30 mesh screen using a Quadro Comill. The resultant powder/granules were collected and #2 capsules were filled with 167.5 mg of granules from Example 1A (67 mg fenofibrate) and 134 mg of granules from Example 1B (67 mg of fenofibrate). [0024]
    • EXAMPLE 2
  • Fenofibrate and Pluronic F68 were melted and mixed in a 1:2 weight ration in a container at approximately 100° C. followed by congealing while mixing at room temperature. The particle size of the congealed solid was reduced to below 30 mesh by grinding and sieving. Granules containing 67 mg of fenofibrate were filled into #2 hard gelatin capsules. [0025]
  • The in vitro dissolution rate of the capsules of Example 1B was compared with that of capsules of Lipanthyl®, a commercial capsule product containing 67 mg of fenofibrate. USP apparatus II was used for testing. The test conditions were: paddle speed=50 rpm; dissolution medium=50 mM SDS solution; temperature=37° C. Dissolution samples were analyzed by an HPLC method. [0026]
  • In vitro dissolution profiles of the reference capsule and capsules from Example 1 of the current invention are shown in FIGS. 1 and 2. This data indicates that dissolution rate of the current invention is more rapid and complete than the reference. Based on U.S. Pat. No. 4,895,726, in vitro dissolution results can be correlated to the in vivo bioavailability in humans. Thus, more rapid and complete dissolution in vitro can result in higher bioavailability in humans. [0027]
    • EXAMPLE 3
  • Fenofibrate, Pluronic F68 and mannitol (4:4:2 weight ratio) were melted and mixed in a container at approximately 100° C. followed by congealing while mixing at room temperature. Particles of the congealed solid were milled through a 30 mesh screen using Quadro Comill. Granules equivalent to 67 mg fenofibrate were filled into a #2 hard gelatin capsule. [0028]
  • In vitro dissolution rate of the capsules of Example 1A were compared with that of the reference, Lipanthyl, the marketed capsule product, which contains the same amount of the active ingredient. USP apparatus II was used for testing. The test conditions were: paddle speed=75 rpm; dissolution medium=100 mM SDS solution; temperature= 37° C. Dissolution samples were analyzed by an HPLC method. [0029]
  • In vitro dissolution profiles of the reference capsule and capsules from Example 1A of the present invention are shown in FIG. 2. Preliminary data indicate that dissolution rate of such capsule of the current invention is equivalent to the reference. Based on U.S. Pat. No. 4,895,726, in vitro dissolution result can be correlated to the in vivo bioavailability in humans. Thus, equivalent dissolution in vitro can result in equivalent bioavailability in humans. [0030]

Claims (15)

1. A process for preparing a solid formulation of a lipid-regulating agent comprising forming a mixture of said lipid-regulating agent with a surfactant; granulating the mixture by melting, mixing, congealing said mixture, optionally with one or more excipients; and optionally forming a finished dosage form.
2. A process of
claim 1
 wherein the lipid-regulating agent is a fibrate.
3. A process of
claim 2
 wherein the fibrate is fenofibrate.
4. A process of
claim 1
 where the surfactant is sodium lauryl sulfate, polyoxamer polyols, block copolymers of ethylene oxide and propylene oxide of the formula HO(C2H4O)R(C2H4O)b(C2H4O)aH, d-alpha tocophenyl polyethylene glycol succinate, or polyoxyl 40 stearate.
5. Process of
claim 4
 where the surfactant is poloxamer polyols.
6. A process of
claim 1
 further comprising adding one or more excipients to the granulated mixture.
7. A process of
claim 6
 wherein the excipient is a pharmaceutically-acceptable excipient, such as, for example, lactose, starch, polyvinyl pyrrolidone or magnesium stearate.
8. A process of
claim 1
 wherein the granulated mixture is milled.
9. A process of
claim 1
 further comprising preparing a finished dosage form.
10. A process of
claim 9
 where the finished dosage form is a tablet.
11. A process of
claim 9
 where the finished dosage form is a capsule.
12. A composition prepared by the process of
claim 1
.
13. A composition prepared by the process of
claim 3
.
14. A method for treating of hyperlipidemia comprising the administration of a formulation prepared by the process of
claim 1
.
15. A method for treating of hyperlipidemia comprising the administration of a formulation prepared by the process of
claim 3
.
US09/240,515 1999-01-29 1999-01-29 Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption Expired - Lifetime US6368622B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/240,515 US6368622B2 (en) 1999-01-29 1999-01-29 Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/240,515 US6368622B2 (en) 1999-01-29 1999-01-29 Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption

Publications (2)

Publication Number Publication Date
US20010006655A1 true US20010006655A1 (en) 2001-07-05
US6368622B2 US6368622B2 (en) 2002-04-09

Family

ID=22906845

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/240,515 Expired - Lifetime US6368622B2 (en) 1999-01-29 1999-01-29 Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption

Country Status (1)

Country Link
US (1) US6368622B2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104060A1 (en) * 1997-01-17 2003-06-05 Andre Stamm Fenofibrate pharmaceutical composition having high bioavailability
US20050101561A1 (en) * 2003-11-07 2005-05-12 Tunac Josefino B. HDL-boosting combination therapy complexes
US20060222706A1 (en) * 2005-03-30 2006-10-05 Moshe Flashner-Barak Formulations of Fenofibrate
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
EP1803441A1 (en) * 2005-12-28 2007-07-04 Teva Pharmaceutical Industries Ltd Pharmaceutical formulations of fenofibrate having improved bioavailability
WO2007075171A1 (en) * 2005-12-28 2007-07-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of fenofibrate having improved bioavailability
US20080031825A1 (en) * 2004-08-20 2008-02-07 Yisheng Chen Pharmaceutical Compositions Comprising Effervescent Agents And Fenofibrate

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025587A1 (en) * 1999-09-13 2002-12-04 Hoffmann La Roche DISPERSION FORMULATIONS CONTAINING LIPASA INHIBITORS
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
WO2005065656A2 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
WO2005065657A2 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US8241670B2 (en) * 2004-04-15 2012-08-14 Chiasma Inc. Compositions capable of facilitating penetration across a biological barrier
US9439126B2 (en) 2005-01-25 2016-09-06 Sipco, Llc Wireless network protocol system and methods
US7872560B2 (en) * 2007-03-19 2011-01-18 Abc Taiwan Electronics Corp. Independent planar transformer
EP2601935A1 (en) * 2007-09-25 2013-06-12 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
US20090202649A1 (en) * 2008-02-06 2009-08-13 Subhash Gore Fenofibrate formulations
CA2725578A1 (en) * 2008-04-24 2009-10-29 Evestra, Inc. Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen
EP3210474B1 (en) * 2008-09-17 2020-11-18 Chiasma, Inc. Pharmaceutical compositions comprising polypeptides and related methods of delivery
DE102012105512A1 (en) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Pharmaceutical form for prolonged release of active ingredients
MA41462A (en) 2015-02-03 2021-05-12 Chiasma Inc METHOD OF TREATMENT OF DISEASES
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
FR2494112B1 (en) 1980-11-19 1986-01-10 Laruelle Claude
IT1180507B (en) 1984-06-29 1987-09-23 Roberto Valducci PROCEDURE FOR THE PREPARATION OF ETOFIBRATE OR SUBSTANCES OF EQUAL OR SIMILAR CHARACTERISTICS, IN MICROGUNULI-DELAY AND PRODUCT OBTAINED WITH SUCH PROCEDURE
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
FR2598146B1 (en) 1986-04-30 1989-01-20 Rech Ind NEW PROCESS FOR THE PREPARATION OF FIBRATES.
FR2602423B1 (en) 1986-08-08 1989-05-05 Ethypharm Sa PROCESS FOR THE PREPARATION OF A FENOFIBRATE-BASED MEDICINAL PRODUCT, OBTAINED BY THIS PROCESS
FR2627696B1 (en) 1988-02-26 1991-09-13 Fournier Innovation Synergie NEW GALENIC FORM OF FENOFIBRATE
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2730231B1 (en) 1995-02-02 1997-04-04 Fournier Sca Lab COMBINATION OF FENOFIBRATE AND VITAMIN E, USE IN THERAPEUTICS
DE19608750A1 (en) 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg Process for the production of fenofibrate preparations

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090035379A1 (en) * 1997-01-17 2009-02-05 Cabinet Hirsch Fenofibrate compositions
US6589552B2 (en) 1997-01-17 2003-07-08 Laboratoires Fournier, S.A. Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US6596317B2 (en) 1997-01-17 2003-07-22 Laboratoires Fournier, Sa Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US6652881B2 (en) 1997-01-17 2003-11-25 Laboratories Fournier, S.A. Fenofibrate pharmaceutical composition having high bioavailability
US20080064759A1 (en) * 1997-01-17 2008-03-13 Paul Royalty Fund Holdings Ii Process for preparing fenofibrate compositions
US7041319B2 (en) 1997-01-17 2006-05-09 Laboratoires Fournier Fenofibrate pharmaceutical composition having high bioavailabilty
US20030104060A1 (en) * 1997-01-17 2003-06-05 Andre Stamm Fenofibrate pharmaceutical composition having high bioavailability
US8343540B2 (en) 1997-01-17 2013-01-01 Laboratories Fournier S.A. Process for producing fenofibrate tablets
US8329214B2 (en) 1997-01-17 2012-12-11 Laboratoires Fournier S.A. Process for producing fenofibrate tablets
US20070190136A1 (en) * 1997-01-17 2007-08-16 Laboratoires Fournier Process for producing fenofibrate tablets
US20070184103A1 (en) * 1997-01-17 2007-08-09 Laboratoires Fournier Process for producing fenofibrate tablets
US20050101561A1 (en) * 2003-11-07 2005-05-12 Tunac Josefino B. HDL-boosting combination therapy complexes
US20080248070A1 (en) * 2003-11-07 2008-10-09 Tunac Josefino B HDL-Boosting Combination Therapy Complexes
US7390504B2 (en) 2003-11-07 2008-06-24 Jj Pharma, Inc. HDL-boosting combination therapy complexes
US8258125B2 (en) 2003-11-07 2012-09-04 Tunac Josefino B HDL-boosting combination therapy complexes
US20100021393A1 (en) * 2004-08-20 2010-01-28 Abbott Laboratories Pharmaceutical Compositions Comprising Effervescent Agents and Fenofibrate
US20080031825A1 (en) * 2004-08-20 2008-02-07 Yisheng Chen Pharmaceutical Compositions Comprising Effervescent Agents And Fenofibrate
US20060222706A1 (en) * 2005-03-30 2006-10-05 Moshe Flashner-Barak Formulations of Fenofibrate
WO2006107316A1 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate containing menthol or peg/poloxamer
WO2006107357A1 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate containing menthol or a peg/poloxamer mixture
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
WO2007075171A1 (en) * 2005-12-28 2007-07-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of fenofibrate having improved bioavailability
EP1803441A1 (en) * 2005-12-28 2007-07-04 Teva Pharmaceutical Industries Ltd Pharmaceutical formulations of fenofibrate having improved bioavailability
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability

Also Published As

Publication number Publication date
US6368622B2 (en) 2002-04-09

Similar Documents

Publication Publication Date Title
US6368622B2 (en) Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6180138B1 (en) Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
AU782282B2 (en) Pharmaceutical composition containing fenofibrate and preparation method
US6383517B1 (en) Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
EP0142561B1 (en) Long-acting nifedipine preparation
EP0636370B1 (en) Sustained release compositions containing morphine
EP0921796B1 (en) Tetrahydrolipstatin containing compositions
MX2007012124A (en) Formulations containing fenofibrate and surfacant mixture.
EP1973531A2 (en) Pharmaceutical compositions
MX2007011858A (en) Improved formulations of fenofibrate containing menthol or peg/poloxamer.
EP1032370B1 (en) Porous hydroxyapatite particles as carriers for drug substances
RU2484816C2 (en) Pharmaceutical compositions of rhein or diacerein
US8062664B2 (en) Process for preparing formulations of lipid-regulating drugs
US20100021393A1 (en) Pharmaceutical Compositions Comprising Effervescent Agents and Fenofibrate
JPH0530810B2 (en)
WO2007024123A1 (en) Pharmaceutical composition of pranlukast solid-dispersion with improved initial dissolution rate and the method of preparing the same
CA2374117A1 (en) Novel formulations comprising lipid-regulating agents
CA2531097C (en) Process for preparing formulations of lipid-regulating drugs
US20060177512A1 (en) Process for preparing formulations of lipid-regulating drugs
JP2007521267A (en) Pharmaceutical compositions based on diclofenac derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: ABBOTT LABORATORIES, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHEN, YISHENG;ENGH, KEVIN R.;YIHONG, QIU;AND OTHERS;REEL/FRAME:009873/0194;SIGNING DATES FROM 19990319 TO 19990405

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: ABBVIE INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ABBOTT LABORATORIES;REEL/FRAME:030167/0463

Effective date: 20120801

FPAY Fee payment

Year of fee payment: 12